🇺🇸 Granisetron Transdermal Patch in United States

FDA authorised Granisetron Transdermal Patch on 12 September 2008 · 10 US adverse-event reports

Marketing authorisations

FDA — authorised 12 September 2008

  • Application: NDA022198
  • Marketing authorisation holder: CUMBERLAND
  • Local brand name: SANCUSO
  • Indication: FILM, EXTENDED RELEASE — TRANSDERMAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Alanine Aminotransferase Increased — 1 report (10%)
  2. Anaemia — 1 report (10%)
  3. Ascites — 1 report (10%)
  4. Aspartate Aminotransferase Increased — 1 report (10%)
  5. Blood Albumin Decreased — 1 report (10%)
  6. Febrile Infection — 1 report (10%)
  7. Hepatic Function Abnormal — 1 report (10%)
  8. Hypoalbuminaemia — 1 report (10%)
  9. Hypokalaemia — 1 report (10%)
  10. Hypomagnesaemia — 1 report (10%)

Source database →

Granisetron Transdermal Patch in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Granisetron Transdermal Patch approved in United States?

Yes. FDA authorised it on 12 September 2008; FDA has authorised it.

Who is the marketing authorisation holder for Granisetron Transdermal Patch in United States?

CUMBERLAND holds the US marketing authorisation.